ACIR
@acir-org.bsky.social
Accelerating Cancer Immunotherapy Research. A free weekly digest of the latest findings in #cancer #immunotherapy. We spotlight promising research and attend major meetings. We also make cool images :)
Gao, He, and Wang et al. show that Trilaciclib (CDK4/6 inhibitor) inhibits NSCLC progression in immunocompetent, but not immunodeficient, mice bearing s.c. LLC and CMT167 tumors. bit.ly/3WUHX19
November 18, 2025 at 12:30 PM
Gao, He, and Wang et al. show that Trilaciclib (CDK4/6 inhibitor) inhibits NSCLC progression in immunocompetent, but not immunodeficient, mice bearing s.c. LLC and CMT167 tumors. bit.ly/3WUHX19
Heyden et al. show that chromatin organizer SATB1 is enriched in TPEX cells and limits exhausted CD8+ T cell expansion and effector differentiation in chronic infection and cancer, while maintaining functionality. bit.ly/47Dwnhc @thedohertyinst.bsky.social @unimelb.bsky.social
November 17, 2025 at 12:30 PM
Heyden et al. show that chromatin organizer SATB1 is enriched in TPEX cells and limits exhausted CD8+ T cell expansion and effector differentiation in chronic infection and cancer, while maintaining functionality. bit.ly/47Dwnhc @thedohertyinst.bsky.social @unimelb.bsky.social
Bachem, Clarke and Kong et al. studied the role of microbiota-derived short chain fatty acids (SCFAs) in an orthotopic melanoma model, revealing a direct link between melanoma control, CD8+ T cell differentiation [...] bit.ly/4p4v40r @thedohertyinst.bsky.social @unimelb.bsky.social
November 14, 2025 at 4:45 PM
Bachem, Clarke and Kong et al. studied the role of microbiota-derived short chain fatty acids (SCFAs) in an orthotopic melanoma model, revealing a direct link between melanoma control, CD8+ T cell differentiation [...] bit.ly/4p4v40r @thedohertyinst.bsky.social @unimelb.bsky.social
To overcome the immunosuppressive TME in glioblastoma, Lunavat and Nieland et al. identified the cell types involved in tumor control following i.t. IL-12 therapy in mice. bit.ly/3XmwCXQ @harvardmed.bsky.social
November 14, 2025 at 12:45 PM
To overcome the immunosuppressive TME in glioblastoma, Lunavat and Nieland et al. identified the cell types involved in tumor control following i.t. IL-12 therapy in mice. bit.ly/3XmwCXQ @harvardmed.bsky.social
Giguelay and Maschmeyer et al. detected only minor differences in the PBMC immune cell composition of 17 cancer patients receiving ICI therapy, 8 with and 9 without severe neurological immune-related adverse events (n-irAEs). bit.ly/49MOC4X @leifludwig.bsky.social
November 13, 2025 at 4:45 PM
Giguelay and Maschmeyer et al. detected only minor differences in the PBMC immune cell composition of 17 cancer patients receiving ICI therapy, 8 with and 9 without severe neurological immune-related adverse events (n-irAEs). bit.ly/49MOC4X @leifludwig.bsky.social
Zhang et al employed cytotoxic B-elemene (ELE)-treated dying cancer cells (DCCs) as an immunogenic cell source within a sprayable fibrin hydrogel (with additional ELE). bit.ly/3JKRBk4
November 13, 2025 at 12:30 PM
Zhang et al employed cytotoxic B-elemene (ELE)-treated dying cancer cells (DCCs) as an immunogenic cell source within a sprayable fibrin hydrogel (with additional ELE). bit.ly/3JKRBk4
Gujar and Cui et al. recently developed N17350 – a cancer-specific therapeutic elastase t – and tested it in a wide range of preclinical models bit.ly/4p8h9GN
November 12, 2025 at 4:00 PM
Gujar and Cui et al. recently developed N17350 – a cancer-specific therapeutic elastase t – and tested it in a wide range of preclinical models bit.ly/4p8h9GN
Wang et al. generated αTIGIT-IL2, an immunocytokine comprising IL-2 and an anti-TIGIT scFv fused to a human IgG1Fc. bit.ly/3Lull4Z
November 11, 2025 at 12:30 PM
Wang et al. generated αTIGIT-IL2, an immunocytokine comprising IL-2 and an anti-TIGIT scFv fused to a human IgG1Fc. bit.ly/3Lull4Z
Khelil et al. demonstrated that SALL4 is overexpressed in multiple tumor types, including primary colorectal cancers and paired liver metastasis, but is silenced in almost all adult tissues. bit.ly/43dpgJD @gustaveroussy.fr
November 10, 2025 at 12:30 PM
Khelil et al. demonstrated that SALL4 is overexpressed in multiple tumor types, including primary colorectal cancers and paired liver metastasis, but is silenced in almost all adult tissues. bit.ly/43dpgJD @gustaveroussy.fr
Tan et al. reported clinical outcomes and translational analyses of patients with early-stage DNA mismatch repair-proficient colon cancer from the phase II NICHE trial. bit.ly/3LoDYHJ @myriamchalabi.bsky.social
November 7, 2025 at 4:45 PM
Tan et al. reported clinical outcomes and translational analyses of patients with early-stage DNA mismatch repair-proficient colon cancer from the phase II NICHE trial. bit.ly/3LoDYHJ @myriamchalabi.bsky.social
Compared to TCRs, CARs have poorer recruitment of proximal signaling molecules and antigen (Ag) sensitivity. bit.ly/3LgQLvQ @stanfordmedicine.bsky.social
November 7, 2025 at 12:45 PM
Compared to TCRs, CARs have poorer recruitment of proximal signaling molecules and antigen (Ag) sensitivity. bit.ly/3LgQLvQ @stanfordmedicine.bsky.social
Sasaki et al. addressed the toxicity of IL-12 that has caused dose-limiting immune-related adverse events (irAEs). bit.ly/43IbhM4 @ko1ssk.bsky.social
November 6, 2025 at 4:45 PM
Sasaki et al. addressed the toxicity of IL-12 that has caused dose-limiting immune-related adverse events (irAEs). bit.ly/43IbhM4 @ko1ssk.bsky.social
Takahashi et al. established a multi-site murine tumor model system for temporal tracking of CD8+ T cell phenotypes and clonal dynamics, identifying a “precursor exhausted” PD-1+Ly108+ population as a driver of clonal expansion. bit.ly/3JFFN2f
November 6, 2025 at 12:30 PM
Takahashi et al. established a multi-site murine tumor model system for temporal tracking of CD8+ T cell phenotypes and clonal dynamics, identifying a “precursor exhausted” PD-1+Ly108+ population as a driver of clonal expansion. bit.ly/3JFFN2f
COVID-19 vaccines aid cancer treatment bit.ly/4nD1cqI @mdanderson.bsky.social
November 5, 2025 at 3:30 PM
COVID-19 vaccines aid cancer treatment bit.ly/4nD1cqI @mdanderson.bsky.social
Using spatial multiomics, Cakmak et al. profiled 642 adult-type diffuse gliomas and identified tertiary lymphoid structures (TLSs) in 15% of the tumors. bit.ly/3JABEN5 @loewe-fci.bsky.social @imkeller.bsky.social
November 4, 2025 at 12:45 PM
Using spatial multiomics, Cakmak et al. profiled 642 adult-type diffuse gliomas and identified tertiary lymphoid structures (TLSs) in 15% of the tumors. bit.ly/3JABEN5 @loewe-fci.bsky.social @imkeller.bsky.social
Across various soluble and cell-bound signals, Avanessian and van den Bijgaart et al. identified IL-2 and IL-15 to be uniquely capable of inducing Flt3L production by immunomodulatory NK cells. bit.ly/3JBJmGP @fredhutch.org
November 3, 2025 at 12:45 PM
Across various soluble and cell-bound signals, Avanessian and van den Bijgaart et al. identified IL-2 and IL-15 to be uniquely capable of inducing Flt3L production by immunomodulatory NK cells. bit.ly/3JBJmGP @fredhutch.org
Ghasemi et al. engineered DC progenitors expressing IL-12 and a non-signaling receptor (EVIR) targeting GD2, which promoted uptake of GD2+ cancer cells and their EVs. bit.ly/47dNbuS
October 31, 2025 at 3:45 PM
Ghasemi et al. engineered DC progenitors expressing IL-12 and a non-signaling receptor (EVIR) targeting GD2, which promoted uptake of GD2+ cancer cells and their EVs. bit.ly/47dNbuS
Afratis et al. focused on disrupting key extracellular matrix (ECM) pathways in the TME by engineering dual-targeting decoys that simultaneously targeted the collagen cross-linking enzyme LOX [...] bit.ly/4oILnQq @weizmanninstitute.bsky.social
October 31, 2025 at 12:00 PM
Afratis et al. focused on disrupting key extracellular matrix (ECM) pathways in the TME by engineering dual-targeting decoys that simultaneously targeted the collagen cross-linking enzyme LOX [...] bit.ly/4oILnQq @weizmanninstitute.bsky.social
Sandén and Landberg et al. demonstrated that lymphoid surface protein SLAMF6 is overexpressed in 60% of primitive AML cells across all subtypes. bit.ly/47LLwNb
October 30, 2025 at 3:30 PM
Sandén and Landberg et al. demonstrated that lymphoid surface protein SLAMF6 is overexpressed in 60% of primitive AML cells across all subtypes. bit.ly/47LLwNb
Cao, Shen, and Fu et al. created ProCTLA-4, a prodrug comprising a misfolded anti-CTLA-4 Ab, correctable by MMP cleavage in the TME. bit.ly/3L6byCf
October 30, 2025 at 11:30 AM
Cao, Shen, and Fu et al. created ProCTLA-4, a prodrug comprising a misfolded anti-CTLA-4 Ab, correctable by MMP cleavage in the TME. bit.ly/3L6byCf
CRATERs have been identified as sites of increased tumor antigen presentation where T cells can recognize and kill tumor cells bit.ly/3J8g42v @ayaludin.bsky.social
October 29, 2025 at 4:45 PM
CRATERs have been identified as sites of increased tumor antigen presentation where T cells can recognize and kill tumor cells bit.ly/3J8g42v @ayaludin.bsky.social
Ling et al. provided a longitudinal multiomic view of human glioblastoma (GBM) evolution under intratumoral oncolytic viral therapy (CAN-3110), demonstrating the feasibility and importance of serial tumor [...] bit.ly/4njSpdc @mgb-neurosurgery.bsky.social
October 28, 2025 at 11:30 AM
Ling et al. provided a longitudinal multiomic view of human glioblastoma (GBM) evolution under intratumoral oncolytic viral therapy (CAN-3110), demonstrating the feasibility and importance of serial tumor [...] bit.ly/4njSpdc @mgb-neurosurgery.bsky.social
To systematically identify recurrent clonal neoepitopes in treatment-resistant patients, Gumbert and Sagie et al. developed and applied the “Spot Neoantigens in Metastases” (SpotNeoMet) pipeline to metastatic [...] bit.ly/49fbCt6 @samuels-lab.bsky.social @yardenasamuels.bsky.social
October 27, 2025 at 11:30 AM
To systematically identify recurrent clonal neoepitopes in treatment-resistant patients, Gumbert and Sagie et al. developed and applied the “Spot Neoantigens in Metastases” (SpotNeoMet) pipeline to metastatic [...] bit.ly/49fbCt6 @samuels-lab.bsky.social @yardenasamuels.bsky.social
🏥 Gut check! Dual neoadjuvant ICB very promising in randomized Phase 1b in CRC doi.org/10.1016/j.cc...
October 26, 2025 at 12:00 PM
🏥 Gut check! Dual neoadjuvant ICB very promising in randomized Phase 1b in CRC doi.org/10.1016/j.cc...
🐠 Finding Nemo -- I mean finding your TCRs! A new tool to easily identify antigen-specific TCRs in clinical samples doi.org/10.1136/jitc...
October 25, 2025 at 12:00 PM
🐠 Finding Nemo -- I mean finding your TCRs! A new tool to easily identify antigen-specific TCRs in clinical samples doi.org/10.1136/jitc...